Dose study of rosuvastatin calcium in the treatment of coronary heart disease and hyperlipidemia.

Objective: To study the clinical efficacy of different doses of rosuvastatin to treat elderly patients with senile coronary heart disease and hyperlipidemia.

Methods: By means of retrospective analysis, 150 elderly patients with coronary heart disease and hyperlipidemia who were treated in Zhangjiakou First Hospital from January 2020 to December 2020 were selected as the study subjects. They were divided into three groups (50 patients in each group) according to the different treatment methods. All patients were given routine treatment for coronary heart disease and hyperlipidemia. At the same time, group A got 5 mg of rosuvastatin calcium per day, group B got 10 mg and group C got C, 20 mg. After 4 months of continuous treatment, changes of blood lipid level, inflammatory factors, and cardiac function in the three groups were compared before and after treatment. Finally, the incidence of adverse reactions in the three groups was statistically compared.

Results: After 4 months of treatment, the levels of TC, LDL, and TG in group B were significantly lower than those of group A, and the levels of HDL were significantly higher than those in group A (P<0.05). There was no significant difference of the above indicators between groups B and C after 4 months of treatment (P>0.05). Using 2 months, 3 months, and 4 months of therapy as time points, the blood lipid levels of the B and C groups was lower than in group A (P<0.05); Serum hs-CRP and TNF of patients in group B and group C after 4 months of treatment were significantly lower than those of group A (P<0.05); The LVEF comparison between groups showed that C was higher than A (P<0.05); The occurrence rate between adverse reactions during the 4 months of medication did not have statistical significance (P>0.05).

Conclusion: Rosuvastatin calcium canimprove the clinical symptoms of elderly patients with coronary heart disease complicated by hyperlipidemia, and can improve the blood lipid level, cardiac function and the level of inflammatory factors in the body, but the clinical effect is not significantly improved by increasing the application dose. This suggests that the daily application dose should be 10 mg.